Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Jefferies Global Healthcare Conference - June 3-5, 2025
Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080
If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
[email protected]
SOURCE: Protagonist Therapeutics
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Three-year-old from Chillicothe diagnosed with cancer; family asks for help
CHILLICOTHE ― Shocking news hit the Allison family on June 1, when something they never thought was possible happened: their three-year-old son, Brandon Jr, was diagnosed with Stage IV Wilms Tumor cancer. Now the family is asking for help with a GoFundMe to help with the ever-growing medical bills that come with a cancer diagnosis, Brandon's mother, Larisa Allison, said. Allison said Wilms Tumor is a rare kidney cancer that affects mainly children. "He had a five-inch tumor on his kidney," Allison said. "They did a couple weeks of chemo before they took out his tumor and his kidney out." Allison said the whole situation has been overwhelming. "He was a perfect, healthy baby boy," Allison said. "Nothing ever wrong with him, nothing ever even bothered him. Chemo isn't even bothering him. He's still crazy, running around right after chemo, like nothing's ever happened to him. He says he's not sick." Allison said her husband has not been able to go to work since his son's first surgery in early July. "My son's first surgery was July 24, so he got that and he healed for a couple of weeks," Allison said. "Then he also had another surgery, where they cut a little piece out of his ling because their was a little nodule in it." The GoFundMe will help Brandon's family pay hospital bills during this time, as he undergoes more chemotherapy and radiation. This article originally appeared on Chillicothe Gazette: Chillicothe family starts GoFundMe for three year old with cancer Solve the daily Crossword
Yahoo
6 minutes ago
- Yahoo
Goldman Traders Say It's Time to Buy the Dip in Momentum Stocks
(Bloomberg) -- Sharp losses in high-flying momentum stocks may present a dip-buying opportunity if history is any guide, according to Goldman Sachs Group Inc.'s trading desk. The traders cited rebounds after similar prior losses in Goldman's High Beta Momentum basket, coupled with the current technical setup. Why New York City Has a Fleet of New EVs From a Dead Carmaker Trump Takes Second Swing at Cutting Housing Assistance for Immigrants Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone Neom's Desert Ski Resort Strains Saudi Prince's $1.5 Trillion Plan When the long-short momentum basket dropped 10% or more over a five-day span in the past, it proceeded to rise in the following week 80% of the time, the traders wrote in a note to clients on Tuesday. The median return was 4.5% in the next week and more than 11% in the next month. The sudden unwind in the momentum strategy, which focuses on buying recent winners and selling short those that are lagging behind, first came amid a rally in the basket's stocks meant to be shorted. But its declines this week were powered more by losses in the long leg of the basket 'as themes such as AI feel the pain of this rotation,' Goldman's traders wrote. The basket fell 13% from Aug. 6 through Aug. 19 after trading near an all-time high. The traders also parsed through technical charts for clues on what could stop the selloff in the momentum trade. The momentum basket is trading near an oversold territory and is approaching the bottom of its so-called regression channel, which is basically the lower boundary of an existing trend. The basket also fell below its 200-day moving average, the level that could serve as a major support. 'It could be a good entry point into the historically rewarded factor, unless tech earnings next week drive a prolonged AI selloff,' Goldman's traders wrote. Nvidia Corp., the biggest member in both the S&P 500 and Nasdaq 100 indexes, is scheduled to release its quarterly results on Aug. 27. Some of the stock market's biggest losers in the past three days include Palantir Technologies Inc., which fell 12%, and Advanced Micro Devices Inc. and Super Micro Computer Inc., which lost 6% or more. Nvidia fell just 2.8% during that time, but its heavy weighting in benchmark indexes made it a drag on the market. Those stocks 'were among the year's most crowded trades, built on optimism toward AI and speculative momentum, making them vulnerable to swift reversals,' Chris Murphy, co-head of derivatives strategy at Susquehanna International Group, wrote in a note. The selloff in the momentum factor, which includes high-flying AI stocks on the long side of the basket, comes amid a variety of concerns in the market including soaring valuations, stretched positioning and increasing competition from China. The Nasdaq 100 Index is trading at 27 times expected 12-month profits, almost a third above its long-term average. Meanwhile, China's warnings to tech firms to avoid one of Nvidia's chips and a drop in cloud-computing company CoreWeave Inc.'s shares after its earnings report were among other recent headwinds to momentum stocks. Another source of concern for tech investors cropped up this week as a Massachusetts Institute of Technology report found that most generative AI initiatives implemented to drive revenue growth are falling flat and only 5% of generative AI pilots are delivering profit. Still, this isn't the only stumble for Goldman's High-Beta Momentum basket this year: This is its fourth retreat of more than 10% in 2025. 'The recent decline in momentum is indicative of how the factor has been trading all year. It's been a frustrating and choppy trade through all of 2025,' said Bloomberg Intelligence's Christopher Cain. 'While the recent decline could be a tactical opportunity, we also point out that that high momentum stocks are showing some of the most expensive valuations compared to low momentum in history.' Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Survived Bankruptcy. Next Up: Cultural Relevance? Women's Earnings Never Really Recover After They Have Children Americans Are Getting Priced Out of Homeownership at Record Rates ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
3 Small-Cap Stocks We Think Twice About
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats. These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here are three small-cap stocks to avoid and some other investments you should consider instead. (CARS) Market Cap: $740.4 million Originally started as a joint venture between several media companies including The Washington Post and The New York Times, (NYSE:CARS) is a digital marketplace that connects new and used car buyers and sellers. Why Does CARS Fall Short? Market opportunities are plateauing as its dealer customers were flat over the last two years Estimated sales growth of 2% for the next 12 months implies demand will slow from its three-year trend Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term At $12.05 per share, trades at 3.5x forward EV/EBITDA. Read our free research report to see why you should think twice about including CARS in your portfolio, it's free. Matthews (MATW) Market Cap: $724.2 million Originally a death care company, Matthews International (NASDAQ:MATW) is a diversified company offering ceremonial services, brand solutions and industrial technologies. Why Are We Out on MATW? Annual sales declines of 6.5% for the past two years show its products and services struggled to connect with the market Earnings per share fell by 14.8% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Cash-burning tendencies make us wonder if it can sustainably generate shareholder value Matthews's stock price of $23.52 implies a valuation ratio of 15.4x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than MATW. CTS (CTS) Market Cap: $1.22 billion With roots dating back to 1896 and a global manufacturing footprint, CTS (NYSE:CTS) designs and manufactures sensors, connectivity components, and actuators for aerospace, defense, industrial, medical, and transportation markets. Why Do We Think Twice About CTS? Annual sales declines of 5.7% for the past two years show its products and services struggled to connect with the market during this cycle Revenue base of $520.9 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale Earnings per share have dipped by 4.5% annually over the past two years, which is concerning because stock prices follow EPS over the long term CTS is trading at $41.55 per share, or 17.3x forward P/E. Check out our free in-depth research report to learn more about why CTS doesn't pass our bar. Stocks We Like More When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
